Advances in pharmacotherapy for angiosarcoma

doi:10.16352/j.issn.1001-6325.2024.10.1363

Abstract

Abstract: Angiosarcoma (AS) is a rare soft tissue sarcoma originating from vascular or lymphatic endothelial cells, accounting for less than 1% of soft tissue sarcomas. It is most common in skin and surface of soft tissue. The diagnosis of AS is based on pathology, and the expression of CD31, ERG and CD34 is commonly positive in immuno-histochemistry. Staging is performed according to the American Joint Committee on Cancer (AJCC)criteria for soft tissue sarcoma. Radical surgery is the primary therapy for locally confined disease. For un-resectable or metastatic angiosarcoma, chemotherapy is the main treatment method. Targeted therapy and immunotherapy have developed rapidly in recent years, and the combined therapy of different types of chemotherapy drug has been the focus of optimization in the future.

Key words: angiosarcoma, chemotherapy, targeted therapy, immunotherapy

CLC Number:

R738.6

References

[1]Lara-Martinez H, Weinberg M, Baratam P,et al. Angiosarcoma of the face: a case study and literature review of local and metastatic angiosarcoma[J]. Case Rep Oncol Med, 2021, 2021: 8823585. doi: 10.1155/2021/8823585.
[2]Young RJ, Natukunda A, Litière S, et al. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials[J]. Eur J Cancer, 2014, 50: 3178-3186.
[3]Verweij J, Lee SM, Ruka W, et al. Randomized phase Ⅱ study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group[J]. J Clin Oncol, 2000, 18: 2081-2086.
[4]D′Angelo SP, Munhoz RR, Kuk D, et al. Outcomes of systemic therapy for patients with metastatic angiosarcoma[J]. Oncology, 2015, 89: 205-214.
[5]Schlemmer M, Reichardt P, Verweij J, et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group[J]. Eur J Cancer, 2008, 44: 2433-2436.
[6]Penel N, Bui BN, Bay JO, et al. Phase Ⅱ trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study[J]. J Clin Oncol, 2008, 26: 5269-5274.
[7]Yonekura S, Endo Y, Fujii H, et al. Clinical benefit of switching from paclitaxel to docetaxel or vice versa in cutaneous angiosarcoma patients resistant to first taxane chemotherapy[J]. J Dermatol, 2023, 50: 1493-1496.
[8]Stacchiotti S, Palassini E, Sanfilippo R, et al. Gemci-tabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network[J]. Ann Oncol, 2012, 23: 501-508.
[9]Agulnik M, Yarber JL, Okuno SH, et al. An open-label, multicenter, phase Ⅱ study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas[J]. Ann Oncol, 2013, 24: 257-263.
[10]Ray-Coquard IL, Domont J, Tresch-Bruneel E, et al. Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: a randomized phase Ⅱ trial[J]. J Clin Oncol, 2015, 33: 2797-2802.
[11]Yoo C, Kim JE, Yoon SK, et al. Angiosarcoma of the retroperitoneum: report on a patient treated with sunitinib[J]. Sarcoma, 2009, 2009: 360875. doi: 10.1155/2009/360875.
[12]Maki RG, D′Adamo DR, Keohan ML, et al. Phase Ⅱ study of sorafenib in patients with metastatic or recurrent sarcomas[J]. J Clin Oncol, 2009, 27: 3133-3140.
[13]Eberst L, Cropet C, Le Cesne A, et al. The off-label use of targeted therapies in sarcomas: the OUTC′S program[J]. BMC Cancer, 2014, 14: 870.doi: 10.1186/1471-2407-14-870.
[14]Ray-Coquard I, Italiano A, Bompas E, et al. Sorafenib for patients with advanced angiosarcoma: a phase Ⅱ Trial from the French Sarcoma Group (GSF/GETO)[J]. Oncologist, 2012, 17: 260-266.
[15]Xu B, Pan Q, Pan H, et al. Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial[J]. eClinicalMedicine, 2023, 64: 102240.doi:10.1016/j.eclinm.2023.102240.
[16]Gu Y, Meng J, Ju Y, et al. Case report:unique FLT4 variants associated with differential response to anlotinib in angiosarcoma[J]. Front Oncol, 2022, 12: 1027696.doi:10.3389/fonc.2022.1027696.
[17]Ogata D, Yanagisawa H, Suzuki K, et al. Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma[J]. Med Oncol, 201,33: 116.doi:10.1007/s12032-016-0831-z.
[18]Liu M, Liu Y, Guo H, et al. Apatinib, combined with chemotherapy or alone is effective in treating angio-sarcoma: a case report[J]. Anticancer Drugs, 2019,30: e0738. doi: 10.1097/CAD.0000000000000738.
[19]Pasquier E, André N, Street J, et al. Effective management of advanced angiosarcoma by the synergistic combination of propranolol and vinblastine-based metronomic chemotherapy: a bench to bedside study[J]. EBioMedicine, 2016, 6: 87-95.
[20]Schlein LJ, Brill SA, Brady RV, et al. Parthenolide as a therapeutic for disseminated canine neoplasms[J]. J Pharmacol Exp Ther,2024, 388: 774-787.
[21]Mendiola M, Saarela J, Escudero FJ, et al. Characterisation of new in vitro models and identification of potentially active drugs in angiosarcoma[J]. Biomed Pharmacother, 2024, 173: 116397. doi: 10.1016/j.biopha.2024.116397.
[22]Rosenbaum E, Antonescu CR, Smith S, et al. Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center[J]. J Immunother Cancer, 2022,10:e004149. doi: 10.1136/jitc-2021-004149.
[23]Florou V, Rosenberg AE, Wieder E, et al. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution[J]. J Immunother Cancer, 2019, 7: 213. doi: 10.1186/s40425-019-0689-7.
[24]Painter CA, Jain E, Tomson BN, et al. The Angio-sarcoma Project: enabling genomic and clinical disco-veries in a rare cancer through patient-partnered research[J]. Nat Med,2020,26: 181-187.
[25]Wagner MJ, Othus M, Patel SP, et al. Multicenter phase Ⅱ trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)[J]. J Immunother Cancer, 2021, 9:e002990.doi: 10.1136/jitc-2021-002990.